Synonyms: compound 206 [WO2018228446A1] | PLB-1004 | PLB1004
Compound class:
Synthetic organic
Comment: The chemical structure for andamertinib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antineoplastic potential. This generated a SMILES match via PubChem to a compound (206) that is claimed in patent WO2018228446A1 (Beijing Adamadle Biotechnology) [2]. Information provided in a clinical trials document (NCT06574347) indicates that andamertinib is a synonym for the clinical candidate PLB1004. PLB1004 is disclosed as an irreversible EGFR inhibitor that is designed to target EGFR with Ex20 insertion mutations [1] (this publication confirms the name to structure match). It is claimed that PLB1004 can cross the blood-brain barrier, meaning that it offers potential to reach metastatic lesions in the brain.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
N-[4-methoxy-2-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-5-[[6-(1-methylindazol-5-yl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
13456 | andamertinib |
Synonyms ![]() |
compound 206 [WO2018228446A1] | PLB-1004 | PLB1004 |
Database Links ![]() |
|
CAS Registry No. | 2254145-43-0 (source: WHO INN record) |
GtoPdb PubChem SID | 507750366 |
PubChem CID | 146498390 |
Search Google for chemical match using the InChIKey | KKPCZGCBAIJCOU-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | KKPCZGCBAIJCOU |
Search PubMed clinical trials | andamertinib |
Search PubMed titles | andamertinib |
Search PubMed titles/abstracts | andamertinib |
UniChem Compound Search for chemical match using the InChIKey | KKPCZGCBAIJCOU-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | KKPCZGCBAIJCOU-UHFFFAOYSA-N |